Do you want to skip to content? Skip to content
Convatec Group Contact Us Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador United Kingdom United Kingdom France France Deutschland Deutschland Italia Italia Україна Україна België België Česko Česko Danmark Danmark España España Ireland Ireland Nederland Nederland Norge Norge Österreich Österreich Polska Polska Schweiz (Deutsch) Schweiz (Deutsch) Slovensko Slovensko Suisse (Français) Suisse (Français) Suomi Suomi Sverige Sverige Türkiye Türkiye Ελλάδα Ελλάδα Россия Россия Bosna i Hercegovina Bosna i Hercegovina България България Eesti Eesti Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta România România Srbija Srbija Slovenija Slovenija الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق New Zealand New Zealand 日本 日本 Australia Australia India India Malaysia Malaysia Singapore Singapore 대한민국 대한민국 中国大陆 中国大陆 中国台湾 中国台湾 ไทย ไทย Indonesia Indonesia Việt Nam Việt Nam Philippines Philippines Hong Kong SAR China (English) Hong Kong SAR China (English) 中国香港特别行政区 (中文(简体,中国香港特别行政区)) 中国香港特别行政区 (中文(简体,中国香港特别行政区))
False /oidc-signin/en-gb/ Convatec Group Contact Us Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador United Kingdom United Kingdom France France Deutschland Deutschland Italia Italia Україна Україна België België Česko Česko Danmark Danmark España España Ireland Ireland Nederland Nederland Norge Norge Österreich Österreich Polska Polska Schweiz (Deutsch) Schweiz (Deutsch) Slovensko Slovensko Suisse (Français) Suisse (Français) Suomi Suomi Sverige Sverige Türkiye Türkiye Ελλάδα Ελλάδα Россия Россия Bosna i Hercegovina Bosna i Hercegovina България България Eesti Eesti Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta România România Srbija Srbija Slovenija Slovenija الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق New Zealand New Zealand 日本 日本 Australia Australia India India Malaysia Malaysia Singapore Singapore 대한민국 대한민국 中国大陆 中国大陆 中国台湾 中国台湾 ไทย ไทย Indonesia Indonesia Việt Nam Việt Nam Philippines Philippines Hong Kong SAR China (English) Hong Kong SAR China (English) 中国香港特别行政区 (中文(简体,中国香港特别行政区)) 中国香港特别行政区 (中文(简体,中国香港特别行政区))

Thalassaemia

Treatments of Thalassaemia with deferoxamine mesylate and neria™ infusion sets.
a woman with her hair blowing in the wind ;

What is thalassaemia?

Thalassaemia is a genetic blood disorder whereby the body makes an abnormal form of hemoglobin – the protein in red blood cells that carries oxygen throughout the body. Without enough normal, healthy red blood cells, oxygen cannot reach all parts of the body and severe anemia occurs.

Complications resulting from thalassaemia

Some patients diagnosed with thalassaemia require regular blood transfusions to raise their hemoglobin blood levels. With each unit of blood transfused, an amount of iron is carried with hemoglobin, leading to iron build-up in the body’s tissue and organs – also referred to as iron overload. As iron can be toxic, too much of it can damage tissue. When excessive iron accumulates in the heart, liver, lungs, brain, and other organs, the risk of disease, and even life-threatening conditions, is high.

Treatment of thalassaemia with deferoxamine mesylate

Thalassaemia patients experiencing iron overload resulting from frequent blood transfusions require an iron removal or chelation therapy. One medication approved for this is deferoxamine mesylate. When using an infusion pump, deferoxamine mesylate is given over several hours, often overnight.*

Continuous subcutaneous infusion with deferoxamine mesylate and neria™ infusion sets

The patient uses an elastomeric pump or a battery-driven, syringe driver infusion pump to deliver a specified continuous amount of deferoxamine mesylate subcutaneously.

The infusion sets should be changed with every treatment. The patient inserts an infusion set under the skin and connects it to the infusion pump.

neria™ infusion sets are tested (in vitro) for use with deferoxamine mesylate.1 The quality and careful design of neria™ infusion sets make them an excellent choice for patients treated with continuous deferoxamine mesylate.

Clinical studies

Clinical studies showed that neria™ infusion sets helped minimize pain2,3 during insertion and reduced needle related traumas.4,5

For complete clinical studies, please contact ConvaTec Infusion Care at info.infusion-set@unomedical.com.

More in Infusion Therapy

Go to page

Infusion Therapy

a child smiling in water

Primary Immune Deficiency

Learn how neria™ infusion sets are used in Primary Immune Defiency treatments.

Read more

Infusion Therapy

a woman with her hair blowing in the wind

Thalassaemia

Treatments of Thalassaemia with Desferal™ and neria™ infusion sets.

Read more

Infusion Therapy

a woman sitting in a chair talking to a man in a chair

Pain management.

Learn how neria™ infusion sets are recommended for Pain Management.

Read more

Infusion Therapy

placeholder image

Parkinson's Disease.

Get an overview of how neria™ contributes to treatment of Parkinson's disease.

Read more
Go to page

1. Parsons J., Infusion Line prefernces of patients prescribed apomorphine for complex Parkinson’s disease. British Journal of Neuroscience Nursing. December 2009, Vol 5 No 12
2. Chan G.C.F., NgD.M.W. Et al, comparison of Subcutaneous Infusion needles for Transfusion-Dependant Thalasseamia Patients by the Intrapersonal Cross-Over Assessment Model, Am.J. Hematol, 76;398-404
3. Drug Device Stability Test Thalaset – Study Desferal (deferoxamine mesilate). July 1, 2005. Data on file. Unomedical.
4. Chan G.C.F, Ng D.M.W. et al, Comparison of Subcutaneous Infusion Needles for Transfusion-Dependent Thalassemia Patients by the Intrapersonal Cross-Over Assessment Model, Am.J.Hematol.76;398-404 (2004).
5. Parsons J. Infusion line preferences of patients prescribed apomorphine for complex Parkinson's disease. British Journal of Neuroscience Nursing. December 2009.Vol 5 No 12 Desferal is a trademark of Novartis AG

Visit our neria.com

Explore the universe of neria™ infusion sets

Click here

You are leaving convatec.com

This Internet site may provide links or references to other sites but Convatec have no responsibility for the content of such other sites and shall not be liable for any damages or injury arising from that content. Any links to other sites are provided as merely a convenience to the users of this Internet site.

Do you wish to continue?